Neptune Technologies (Nasdaq: NEPT ) suffered a major setback in a tragic explosion to its main production facility in Quebec on Nov. 8. Since then and up until today, trading in the company's shares had been frozen. Markets reacted by sending shares down 24%, reflecting the major production setback from the destroyed facility. The loss will impact the company's main product, a krill-oil-based nutritional supplement. However, one of its subsidiaries has aspirations to compete with fish-oil based pharmaceuticals from companies such as Amarin (Nasdaq: AMRN ) and GlaxoSmithKline (NYSE: GSK ) .
For Amarin, the success of its new triglyceride lowering drug is key to the company's future success or failure, and is a hugely followed story on Fool.com. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.